DISCOUNT OPTIONSSCHEIN - MADRIGAL PHARMACEUTICALS | Market Closed - Börse Stuttgart 03:06:40 2024-05-17 pm EDT | ||
| 0.38 EUR | 0.00% |
|
| Current month | -7.32% | ||
| 1 month | -22.45% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about MADRIGAL PHARMACEUTICALS, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-05-17 | 0.38 | 0.00% |
| 24-05-16 | 0.38 | +18.75% |
| 24-05-15 | 0.32 | 0.00% |
| 24-05-14 | 0.32 | +6.67% |
| 24-05-13 | 0.3 | +7.14% |
Delayed Quote Börse Stuttgart
Last update May 17, 2024 at 03:06 pm EDT
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | MADRIGAL PHARMACEUTICALS, INC. |
| Issuer | Morgan Stanley |
| WKN | MG0FT9 |
| ISIN | DE000MG0FT90 |
| Date issued | 2024-03-20 |
| Strike | 350 $ |
| Maturity | 2024-09-20 (124 Days) |
| Parity | 10 : 1 |
| Emission price | 0.51 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.79 € |
|---|---|
| Lowest since issue | 0.26 € |
| Spread | 0.06 € |
| Spread % | 13.95% |
Company Profile
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-β (THR-β) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Companyâs clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.
Sector
-
Consensus: Madrigal Pharmaceuticals, Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
220.1
USD
Average target price
363.9
USD
Spread / Average Target
+65.34%
- Stock Market
- Certificates
- Certificat
